Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists
- 1 January 1994
- journal article
- clinical trial
- Published by Elsevier in Bone and Mineral
- Vol. 26 (1) , 19-26
- https://doi.org/10.1016/s0169-6009(08)80159-6
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Leuprolide acetate and bone mineral density measured by quantitative digitized radiographyFertility and Sterility, 1993
- Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trialJournal of Clinical Endocrinology & Metabolism, 1992
- Gonadotropin-releasing hormone agonists: Strategies formanaging the hypoestrogenic effects of therapyAmerican Journal of Obstetrics and Gynecology, 1992
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists?Journal of Clinical Endocrinology & Metabolism, 1990
- Effects of nafarelin on bone densityAmerican Journal of Obstetrics and Gynecology, 1990
- Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazolFertility and Sterility, 1989
- The Effect of a Gonadotropin-Releasing Hormone Agonist Analog (Nafarelin) on Bone MetabolismJournal of Clinical Endocrinology & Metabolism, 1988
- REVERSIBLE TRABECULAR BONE DENSITY LOSS FOLLOWING INDUCED HYPO‐OESTROGENISM WITH THE GnRH ANALOGUE BUSERELIN IN PREMENOPAUSAL WOMENClinical Endocrinology, 1988
- Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women.BMJ, 1987
- LHRH ANALOGUES AND BONE LOSSThe Lancet, 1987